Characteristics, Disease Burden and Healthcare Resource Use of Moderate and Severe Atopic Dermatitis in Australia
Nearly all participants experienced sleep disturbances, and the prevalence of anxiety and depression was high. Active flares in AD were frequent. Work and social impairment in moderate-to-severe AD was significant, including for many receiving currently available advanced therapies. There remains a need for new treatments in Australia to alleviate the current AD burden.
Authors
- Sam Colman (ORCID: https://orcid.org/0000-0002-7749-6345)
- Alan R. Townsend (ORCID: https://orcid.org/0009-0005-4338-5996)
- John Su (ORCID: https://orcid.org/0000-0002-4021-5423)
- Rachel S. Newson (ORCID: https://orcid.org/0000-0002-2653-5797)
- Laura Kauffman
- Kathryn Gibson (ORCID: https://orcid.org/0000-0003-2331-0311)
Institutions
- Eli Lilly (United States) (US)
- UNSW Sydney (AU)
- Eastern Health (AU)
- Nokia (Australia) (AU)
- Monash University (AU)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1111/ajd.14619
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company